Free Account Opening + AMC Free Demat
Loading...

Ajanta Pharma Buyback vs Weizmann Buyback

Comparision between Ajanta Pharma Buyback and Weizmann Buyback.

Buyback Details

Ajanta Pharma Buyback is a Tender Offer buyback proposed to list at BSE, NSE while Weizmann Buyback is a Tender Offer proposed to list at BSE, NSE.

  Ajanta Pharma Limited Weizmann Limited
Logo Ajanta Pharma Buyback Logo Weizmann Buyback Logo
Type of Buyback Tender Offer Tender Offer
Listing At BSE, NSE BSE, NSE
Face Value ₹2 per share ₹10 per share
Buyback Price ₹2550 per share ₹60 per share
Issue Size 11,20,000 shares 14,12,515 shares
Issue Size (Amount) ₹285.60 Crores ₹8.48 Crores
Buyback Ratio
Category Entitlement Ratio of Buyback
Reserved Category for Small Shareholders 30 Equity Shares out of every 151 shares held on the record date.
General Category for all other Eligible Shareholders 1 Equity Shares out of every 91 shares held on the record date.
Category Entitlement Ratio of Buyback
Reserved Category for Small Shareholders 35 Equity Shares out of every 284 shares held on the record date.
General Category for all other Eligible Shareholders 43 Equity Shares out of every 557 shares held on the record date.
Registrar Link Intime India Private Ltd Bigshare Services Pvt Ltd
Lead Managers Vivro Financial Services Private Limited Keynote Financial Services Ltd
Necessity of the buyback

The Buyback aims to :
i) Distribute surplus funds to shareholders and thereby enhance their overall return.
ii) Improve financial ratios like Earnings per share (EPS), Return on assets (ROA) and Return on Equity (ROE).

The Buyback aims to :
i) Distribute surplus funds to shareholders and thereby enhance their overall return.
ii) Improve financial ratios like Earnings per share (EPS), Return on assets (ROA) and Return on Equity (ROE).

Buyback Timetable

Ajanta Pharma Buyback and Weizmann Buyback buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Ajanta Pharma Buyback Buyback record date is Jan 14, 2022. Weizmann Buyback Buyback record date is Dec 10, 2021.

  Ajanta Pharma Limited Weizmann Limited
Record Date Jan 14, 2022 Dec 10, 2021
Offer Open Date Feb 03, 2022 Jan 13, 2022
Offer Closure Date Feb 16, 2022 Jan 27, 2022
Last date for receipt of tender forms Feb 16, 2022 Jan 27, 2022
Finalisation of buyback Feb 24, 2022 Feb 04, 2022
Last Date for settlment of bids Feb 25, 2022 Feb 07, 2022
Last Date for extinguishment of shares Mar 04, 2022 Feb 14, 2022

Financial Details and Other Relevent Information

Comparison of Ajanta Pharma Buyback and Weizmann Buyback financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

  Ajanta Pharma Limited Weizmann Limited
Financial
Summary of financial Information Consolidated)
Particulars For the year/period ended (Rs. in Crores)
  30-Sep-21 31-Mar-21 31-Mar-20
Total Income 1,694.96 2,915.67 2,680.06
Profit After Tax 369.69 653.87 467.70
Net Worth 3,358.90 2,995.63 2,598.87
Reserves and Surplus 3,341.51 2,978.24 2,581.33
Summary of financial Information Consolidated)
Particulars For the year/period ended (Rs. in Millions)
  30-Sep-21 31-Mar-21 31-Mar-20 31-Mar-19
Total Income 464.21 982.82 964.82 1,066.67
Profit After Tax -0.89 49.22 43.20 85.69
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2021 2239.10 2015.80 2136.74
Oct-2021 2366.30 2053.65 2213.24
Sep-2021 2340.00 2112.70 2199.31

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2021 55.70 50.50 52.86
Oct-2021 65.00 45.75 54.26
Sep-2021 51.65 46.00 47.95
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2021 2239.10 2000.00 2137.44
Oct-2021 2365.80 2053.65 2213.37
Sep-2021 2330.00 2110.00 2201.05

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2021 55.50 50.60 52.90
Oct-2021 64.40 46.10 54.10
Sep-2021 50.85 45.40 47.89

Comments

Add a public comment...